Henry Schein Medical Joins Defibtech and the Professional Football Athletic Trainers Society Foundation to Donate Automated External Defibrillators for Young Athletes Across the Country
Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), Defibtech, and the Professional Football Athletic Trainers Society Foundation Inc. (PFATS Foundation), are coming together to donate and distribute automated external defibrillators (AEDs). Recognizing the importance of having AEDs readily available for student athletes,…
Doximity Report Indicates Permanent Role for Telemedicine in Health Care
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2023 State of Telemedicine Report, revealing that nearly 88% of U.S. physicians surveyed believe telemedicine has increased patient access to health care, particularly among populations that…
McKesson ideaShare Recognizes Excellence in Community Pharmacy
More than 2,800 attendees including pharmacists, independent pharmacy owners, technicians, exhibitors and McKesson experts came together last week at the 2023 McKesson ideaShare conference in Las Vegas. The annual event, which is hosted by McKesson Corporation, Health Mart, and Health Mart Atlas, is the leading…
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and…
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for fidanacogene elaparvovec for the treatment of adults with hemophilia B. In parallel, the European marketing authorization application (MAA)…
From general to personalized care: GE HealthCare is focused on disease detection and more holistic and effective treatment options
The company will showcase its latest innovative solutions to enable rapid diagnosis, Theranostics, and precision care at #SNMMI23 CHICAGO — At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting, GE HealthCare (Nasdaq: GEHC) is proud to…
Doximity Report Indicates Permanent Role for Telemedicine in Health Care
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2023 State of Telemedicine Report, revealing that nearly 88% of U.S. physicians surveyed believe telemedicine has increased patient access to health care, particularly among populations that…
The Worldwide At-Home Diagnostic Testing Market to 2027 – Surging Demand for Early Disease Diagnosis, Personalized Medicine & Expanded Technologies Drives Growth – ResearchAndMarkets.com
The At-Home in vitro diagnostic (IVD) testing market is comprised of IVD tests that can be purchased at the local store or on the Internet where the patient gathers the specimen and results are displayed usually within minutes. Generally, these…
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patients with tumor cell…
Ribbon Biolabs Appoints Roopom Banerjee as Executive Chairman
Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors. He brings 25 years of strategy, operations, business development, financial advisory, and investment experience in early and late-stage life…
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023…
Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More
Dexcom, Inc.(NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people living with diabetes, announced today its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured…